Search alternatives:
substantial decrease » substantial increase (Expand Search), substantially increased (Expand Search)
significant case » significant cause (Expand Search), significant based (Expand Search), significant change (Expand Search)
case based » made based (Expand Search), game based (Expand Search), rate based (Expand Search)
substantial decrease » substantial increase (Expand Search), substantially increased (Expand Search)
significant case » significant cause (Expand Search), significant based (Expand Search), significant change (Expand Search)
case based » made based (Expand Search), game based (Expand Search), rate based (Expand Search)
-
101
Base-case results.
Published 2025“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”
-
102
-
103
Base-case results.
Published 2024“…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …”
-
104
Base-case analysis.
Published 2023“…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120